Literature DB >> 24793675

Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Tuomas Kiviniemi1, Marja Puurunen2, Axel Schlitt3, Andrea Rubboli4, Pasi Karjalainen5, Saila Vikman6, Matti Niemelä7, Heli Lahtela8, Gregory Y H Lip9, K E Juhani Airaksinen8.   

Abstract

The hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, and drugs/alcohol (HAS-BLED); anticoagulation and risk factors in atrial fibrillation (ATRIA); modified Outpatient Bleeding Risk Index (mOBRI); and reduction of atherothrombosis for continued health (REACH) schemes are validated bleeding risk-prediction tools, but their predictive performance in patients with AF receiving multiple antithrombotic drugs after percutaneous coronary intervention (PCI) is unknown. We sought to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing PCI. Management of patients with AF undergoing coronary artery stenting is a multicenter European prospective registry enrolling patients with AF undergoing PCI. We calculated HAS-BLED, ATRIA, mOBRI, and REACH bleeding risk-prediction scores and assessed the rate of bleeding complications as defined by Bleeding Academic Research Consortium at 12 months follow-up in 929 consecutive patients undergoing PCI. Increasing age, femoral access site, and previous peptic ulcer were independent determinants of bleeding. Low bleeding risk scores as determined by HAS-BLED 0 to 2, ATRIA 0 to 3, mOBRI 0, and REACH 0 to 10 were detected in 23.7%, 73.0%, 7.8%, and 5.7% of patients of the cohort, respectively. No significant differences were detected in the rates of any bleeding or major bleeding events for low versus intermediate/high scores with each risk-prediction tool. In conclusion, the performance of ATRIA, HAS-BLED, mOBRI, and REACH scores in predicting bleeding complications in this high-risk patient subset was useless.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24793675     DOI: 10.1016/j.amjcard.2014.03.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome.

Authors:  Diego Castini; Simone Persampieri; Ludovico Sabatelli; Massimo Erba; Giulia Ferrante; Federica Valli; Marco Centola; Stefano Carugo
Journal:  Heart Vessels       Date:  2019-04-10       Impact factor: 2.037

Review 2.  Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Authors:  Bharath Rajagopalan; Christopher Madias
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-07

3.  Hemodynamic parameters predict the risk of atrial fibrillation after cardiac surgery in adults.

Authors:  Rongxin Lu; Nan Ma; Zhaolei Jiang; Ju Mei
Journal:  Clin Cardiol       Date:  2017-08-29       Impact factor: 2.882

Review 4.  Ischemic Stroke: Risk Stratification, Warfarin Teatment and Outcome Measure.

Authors:  Srikanth Kaithoju
Journal:  J Atr Fibrillation       Date:  2015-12-31

5.  Predicting the outcome of hip fracture patients by using N-terminal fragment of pro-B-type natriuretic peptide.

Authors:  Pauliina Nordling; Tuomas Kiviniemi; Marjatta Strandberg; Niko Strandberg; Juhani Airaksinen
Journal:  BMJ Open       Date:  2016-02-24       Impact factor: 2.692

6.  Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study.

Authors:  Aissa Bah; Ilpo Nuotio; Antti Palomäki; Pirjo Mustonen; Tuomas Kiviniemi; Antti Ylitalo; Päivi Hartikainen; K E Juhani Airaksinen; Juha E K Hartikainen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  A predictive nomogram of bleeding risk in patients with atrial fibrillation after drug-eluting stent implantation.

Authors:  Jun Qian; Jiyong Zan; Lijun Kuang; Lin Che; Yunan Yu; Ting Shen; Jiani Tang; Fei Chen; Xuebo Liu
Journal:  Ann Transl Med       Date:  2021-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.